Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: A retrospective study of 138 patients

Archives of Dermatology

Volumn 147, Issue 3, 2011, Pages 286-291

  Charneux, Julie ^a   Lorin, Johanna ^a   Vitry, Fabien ^c   Antonicelli, Frank ^a   Reguiai, Ziad ^a   Barbe, Coralie ^c   Tabary, Thierry ^b   Grange, Florent ^a   Bernard, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BASEMENT MEMBRANE ANTIBODY; BULLOUS PEMPHIGOID ANTIGEN 1; COLLAGEN TYPE 17;

AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLISTER; BLOOD SAMPLING; BULLOUS PEMPHIGOID; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HUMAN; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

AGED; AUTOANTIBODIES; AUTOANTIGENS; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 79952859900     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.23     Document Type: Article

References (34)

1. Bernard P, Vaillant L, Labeille B, et al; Bullous Diseases French Study Group. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Dermatol. 1995;131(1):48-52.
2. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol. 2007;23:257-288.
3. Schmidt E, Bröcker EB, Zillikens D. New aspects on the pathogenesis of bullous pemphigoid. Hautarzt. 2000;51(9):637-645.
4. Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108(8):1151-1158. (Pubitemid 32995373)
5. Hamada T, Nagata Y, Tomita M, Salmhofer W, Hashimoto T. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol. 2001;10(4):256-263. (Pubitemid 32754994)
6. Hashimoto T, Amagai M, Ebihara T, et al. Further analyses of epitopes for human monoclonal anti-basement membrane zone antibodies produced by stable human hybridoma cell lines constructed with Epstein-Barr virus transformants. J Invest Dermatol. 1993;100(3):310-315. (Pubitemid 23083184)
7. Ide A, Hashimoto T, Amagai M, Tanaka M, Nishikawa T. Detection of autoantibodies against bullous pemphigoid and pemphigus antigens by an enzymelinked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol. 1995;4(2):112-116.
8. Rico MJ, Korman NJ, Stanley JR, Tanaka T, Hall RP. IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA. J Immunol. 1990;145(11):3728-3733.
9. Rico MJ, Hashimototo T, Watanabe K, Hall RP, Clark RB, Nishikawa T. Comparative epitope mapping of sera from United States (US) and Japanese patients with bullous pemphigoid (BP) to fusion proteins encoded by BPAG1. J Dermatol Sci. 1996;12(3):238-245. (Pubitemid 26290410)
10. Tanaka M, Hashimoto T, Amagai M, et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol. 1991;97(4):725-728.
11. Skaria M, Jaunin F, Hunziker T, et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol. 2000;114(5):998-1004. (Pubitemid 30252723)
12. Di Zenzo G, Grosso F, Terracina M, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol. 2004;122(1):103-110. (Pubitemid 38114646)
13. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti- BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 1994;102(6):878-881. (Pubitemid 24210382)
14. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109(5):679-683. (Pubitemid 27465925)
15. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002;30(3):224-232. (Pubitemid 35351315)
16. Sakuma-Oyama Y, Powell AM, Oyama N, Albert S, Bhogal BS, Black MM. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol. 2004;151(1):126-131. (Pubitemid 39061289)
17. Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180-specific autoantibodies in bullous pemphigoid. J Invest Dermatol. 2004;122(6):1413-1422. (Pubitemid 38757223)
18. Tsuji-Abe Y, Akiyama M, Yamanaka Y, Kikuchi T, Sato-Matsumura KC, Shimizu H. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37(3):145-149. (Pubitemid 40331924)
19. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174-178. (Pubitemid 30090755)
20. Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol. 2009;145(5):537-542.
21. Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol. 2004;111(1):146-152. (Pubitemid 38482094)
22. Tampoia M, Lattanzi V, Zucano A, et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci. 2009;1173:15-20.
23. Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci. 2006;41(1):21-30. (Pubitemid 43075429)
24. Vaillant L, Bernard P, Joly P, et al; French Bullous Study Group. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol. 1998;134(9):1075-1080.
25. Wieland CN, Comfere NI, Gibson LE, Weaver AL, Krause PK, Murray JA. Antibullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol. 2010;146(1):21-25.
26. Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol. 2004;151(5):1004-1010. (Pubitemid 39573888)
27. Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997;136(5):694-698. (Pubitemid 27278076)
28. Joly P, Roujeau JC, Benichou J, et al; Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. (Pubitemid 34438839)
29. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell DF. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2005;(3):CD002292.
30. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681-1687.
31. Pas HH, de Jong MC, Jonkman MF, Heeres K, Slijper-Pal IJ, van der Meer JB. Bullous pemphigoid: serum antibody titre and antigen specificity. Exp Dermatol. 1995;4(6):372-376.
32. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113(8):1043-1046.
33. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26(4):585-589.
34. Tanaka M, Hashimoto T, Dykes PJ, Nishikawa T. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Clin Exp Dermatol. 1996;21(1):23-27. (Pubitemid 26167415)